Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Friedlander

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
International Journal of Cancer|May 9, 2008
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiencyJia-Lin Yang, Xian-Jun Qu, Yan Yu, et al.
Patient Related Outcome Measures|May 15, 2023
Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical PracticeRachel Campbell, Madeleine T King, Martin R Stockler, et al.
Gynecologic Oncology|September 5, 2021
Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatmentRachel Campbell, Madeleine T King, Tanya L Ross, et al.
Experimental Neurology|October 23, 2010
Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathySusanna B Park, Cindy S-Y Lin, Arun V Krishnan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2009
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicitySusanna B Park, David Goldstein, Cindy S-Y Lin, et al.
Brain : a Journal of Neurology|September 12, 2009
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathySusanna B Park, Cindy S-Y Lin, Arun V Krishnan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 20, 2012
Impact of oxaliplatin-induced neuropathy: a patient perspectiveBarbara K Bennett, Susanna B Park, Cindy S-Y Lin, et al.
The Oncologist|April 12, 2011
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibilitySusanna B Park, Cindy S Y Lin, Arun V Krishnan, et al.
Therapeutic Advances in Medical Oncology|August 11, 2018
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysisKatrin M Sjoquist, Sarah J Lord, Michael L Friedlander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?Michael L Friedlander, Martin Richard Stockler, Phyllis Butow, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
International Journal of Cancer|May 9, 2008
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiencyJia-Lin Yang, Xian-Jun Qu, Yan Yu, et al.
Patient Related Outcome Measures|May 15, 2023
Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical PracticeRachel Campbell, Madeleine T King, Martin R Stockler, et al.
Gynecologic Oncology|September 5, 2021
Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatmentRachel Campbell, Madeleine T King, Tanya L Ross, et al.
Experimental Neurology|October 23, 2010
Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathySusanna B Park, Cindy S-Y Lin, Arun V Krishnan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2009
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicitySusanna B Park, David Goldstein, Cindy S-Y Lin, et al.
Brain : a Journal of Neurology|September 12, 2009
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathySusanna B Park, Cindy S-Y Lin, Arun V Krishnan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 20, 2012
Impact of oxaliplatin-induced neuropathy: a patient perspectiveBarbara K Bennett, Susanna B Park, Cindy S-Y Lin, et al.
The Oncologist|April 12, 2011
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibilitySusanna B Park, Cindy S Y Lin, Arun V Krishnan, et al.
Therapeutic Advances in Medical Oncology|August 11, 2018
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysisKatrin M Sjoquist, Sarah J Lord, Michael L Friedlander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?Michael L Friedlander, Martin Richard Stockler, Phyllis Butow, et al.
Pageof 9